Phase II trial of lymphoblastoid interferon in metastatic malignant melanoma. 1985

R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe

Thirty-three patients with metastatic malignant melanoma, some of whom had received previous chemotherapy, immunotherapy, or radiotherapy, were entered in a trial of three different doses and schedules of administration of lymphoblastoid alpha interferon. The overall response rate was 9%; some patients had long-lasting response and two achieved complete response. There was no clear advantage to any one regimen. Dose-related flu-like syndrome, granulocytopenia, hepatocellular enzyme elevation, and anemia were observed as the most common toxic effects. Interferon deserves further study in the treatment of malignant melanoma.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
November 1983, Cancer treatment reports,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
November 2007, Anti-cancer drugs,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
January 1987, Cancer immunology, immunotherapy : CII,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
July 1986, Cancer,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
May 1984, Cancer treatment reports,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
October 1983, American journal of clinical oncology,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
January 1994, Investigational new drugs,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
January 1988, Acta oncologica (Stockholm, Sweden),
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
January 1987, Journal of cancer research and clinical oncology,
R M Goldberg, and M Ayoob, and R Silgals, and J D Ahlgren, and J R Neefe
October 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!